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The modulation of CD40L activity might represent a promising therapeutic target to reduce monocyte inﬂammatory functions
in chronic diseases, such as rheumatoid arthritis. In the present study, we investigated the possible inﬂuence of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) on CD40L-induced monocyte survival. Monocytes were isolated from buﬀy coats by using
Ficoll-Percoll gradients. Monocyte apoptosis was evaluated by ﬂuorescence microscopy on cytopreps stained with acridine
orange or using ﬂow cytometry analysis of Annexin-V and Propidium Iodide staining. Akt and NF-κB activation was assessed
using western blot. Caspase 3 activity was determined spectrophotometrically. Among diﬀerent NSAIDs, only oxaprozin dose-
dependentlyincreasedapoptosisofCD40L-treatedmonocytes.Oxaprozinpro-apoptoticactivitywasassociatedwiththeinhibition
of CD40L-triggered Akt and NF-κB phosphorylation and the activation of caspase 3. In conclusion, our data suggest that
oxaprozin-induced apoptosis in CD40L-treated human monocytes is associated with previously unknown cyclooxygenase (COX)-
independent pathways. These intracellular proteins might be promising pharmacological targets to increase apoptosis in CD40L-
treated monocytes.
Copyright © 2009 Fabrizio Montecucco et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Human monocytes are central players in the pathogenesis
of chronic inﬂammatory disorders, such as atherosclerosis
and rheumatoid arthritis [1–3]. Monocytes are immune
cells circulating in the blood stream, which are recruited to
inﬂammatory sites for the immune response [2, 4]. Once
residentininﬂamedtissues,theycandiﬀerentiateintoseveral
cell types, such as macrophages, dendritic cells, and also
osteoclast-like cells [5–7] contributing to further increase
inﬂammation. In this context, the induction of monocyte
apoptosis with the consequent reduction of inﬂammatory
cell inﬁltrates has to be considered as a crucial target
to reduce inﬂammatory disease persistence. CD40 ligand
(CD40L) is a crucial mediator in monocyte functions and
diﬀerentiation [8]. Thus, the modulation of CD40L-induced
proinﬂammatory activities could represent a very promising
therapeutic strategy to reduce monocyte-mediated tissue
inﬁltration and injury. In the present article, we planned
to investigate the possible inﬂuence of nonsteroidal anti-
inﬂammatory drugs (NSAIDs) on CD40L-treated monocyte
apoptosis [9, 10]. In particular, we focused on oxaprozin,
an achiral oxazole-propionic acid derivative (4,5-diphenyl-
2-oxazolepropionic acid) that has been recently shown to
modulate monocyte survival in inﬂammatory microenvi-
ronments [11]. In order to identify the possible molec-
ular mechanisms involved in, we studied the role of
diﬀerent intracellular mediators, such as cyclooxygenase2 Journal of Biomedicine and Biotechnology
(COX), phosphoinositol-3 kinase (PI3K)/Akt, extracellu-
lar signal-regulated kinase (ERK) 1/2, p38 mitogen acti-
vated kinase (MAPK), nuclear factor kappaB (NF-κB), and
caspase 3.
2.MaterialsandMethods
2.1. Human Monocyte Isolation. Human monocytes were
isolated from buﬀy coats, obtained from healthy volunteers,
underaprotocolapprovedbythelocalEthicsCommittee.All
donors provided written, informed consent to the procedure
and use of the cells. After centrifugation on a Ficoll-Hypaque
density gradient, mononuclear cells were collected from
the interface and washed with PBS. Monocytes were then
puriﬁed from the upper interface of a hypotonic Percoll
density gradient (1.129g/mL). Puriﬁed monocytes were
resuspended in RPMI 1640 medium supplemented with 1%
(v/v) heat-inactivated fetal calf serum (FCS) and 500ng/mL
polymyxin B, as previously described [12]. At the end of
puriﬁcation, viability of monocytes was more than 98%,
as determined by ethidium bromide-ﬂuoresceine diacetate
assay (from Sigma-Aldrich S.r.l., Milano, Italy). Monocyte
purity was at least 90%, as assessed by ﬂow cytometric
analysis (staining with FITC-conjugated antihuman CD14
antibody (Ab), from BD Pharmingen, Franklin Lakes, NJ)
and nonspeciﬁc esterase staining.
2.2. Assessment of Monocyte Apoptosis. Puriﬁed monocytes
were resuspended at 106/mL and cultured for 48 hours in
culture medium containing RPMI 1640 with 25mM HEPES
(Irvine Scientiﬁc, Santa Ana, CA), 500ng/mL polymixin
B (Sigma-Aldrich), and 1% heat-inactivated FCS (ICN
Biomedicals s.r.l., Milano, Italy) in the presence or absence
of 200ng/mL CD40L plus 1μg/mL CD40L enhancer (both
from Alexis Biochemicals, Carlsbad, CA). In selective exper-
iments, cells were cultured in the presence or absence
of 50μM PD98059 (MEK inhibitor, a kinase activating
ERK 1/2, from Biomol Research Laboratories, Inc., Ply-
mouth Meeting, PA), 1μM SB203580 (p38 MAPK inhibitor,
from Biomol Research Laboratories, Inc.), 50μM LY294002
(PI3K inhibitor, from Sigma-Aldrich), 20μMS N - 5 0( N F -
κB inhibitor, from Calbiochem, San Diego, CA), 50μM
Ac-DEVD-CHO (caspase 3 inhibitor, from Bachem AG,
Bubendorf, Switzerland), diﬀerent doses (5, 10, 50, 100μM)
of oxaprozin (Helsinn Healthcare SA, Lugano, Switzerland),
100μM ibuprofen (Sigma-Aldrich),100μM indomethacin
(Sigma-Aldrich), or 100μM naproxene (Sigma-Aldrich).
Percentages of apoptotic cells were measured by both
ﬂuorescence microscope (staining with acridine orange from
Sigma-Aldrich and Annexin V-FITC Kit, from MBL Interna-
tional, Woburn, MA) and ﬂow cytometer (by using Propid-
ium Iodide Kit, from MBL International). Immunoﬂuores-
ence analysis of Annexin V and Propidium iodide binding
was performed by following the manufacturer’s instructions
with minor changes, as previously described [13].
2.3. Immunoblot Analysis. 107 cells/mL monocytes were
prencubated in the presence or absence of 100μMo x a p r o z i n
for 1 hour in a humidiﬁed atmosphere 5%CO2 at 37
◦Ca n d
then, without washing, stimulated in the presence or absence
of 200ng/mL CD40L plus 1μg/mL CD40L enhancer, for 15
minutes.Thereactionwasstoppedonice,andcellswerecen-
trifuged at 4◦C to remove culture supernatants. Total protein
was extracted in lysis buﬀer containing 20mM Tris·HCl (pH
7.5),150mMNaCl,10mMNaF,1%NonidetP-40,10%glyc-
e r o l ,1m MP M S F ,1 0μg/mL aprotinin, 10μg/mL leupeptin,
and 0.5mM Na3VO4. Proteins (40μg) were electrophoresed
through polyacrylamide-SDS gels and transferred by elec-
troblotting onto nitrocellulose membranes, as previously
[14]. Membranes were blocked for 1 hour in 5% (wt/vol)
nonfat milk and then stained with monoclonal antihuman
phosphorylated (p)-p65 NFκB, monoclonal antihuman p-
Akt (both from Santa Cruz Biotechnology, Santa Cruz, CA),
polyclonal antihuman p-p38 MAPK, or monoclonal antihu-
man p-ERK 1/2 Abs (both from R&D System, Minneapolis,
MN).
2.4. Caspase 3 Activity. Caspase 3 activity in the presence
or absence of 200ng/mL CD40L plus 1μg/mL CD40L
enhancerand100μMoxaprozinwasperformedaspreviously
described [15]. The enzymatic activity was spectrophoto-
metrically determined (Titertek TwinReader Plus, Flow Lab,
Ltd, Irvine, Scotland) for 60 minutes at 405nm assuming an
extinction coeﬃcient of 8.8 ×103M1cm−1.
2.5. Statistical Analysis. Statistical analysis was performed by
using one-way ANOVA with Bonferroni’s posttest (Graph-
PadInStat version3.05forWindows XP,GraphPadSoftware,
San Diego, CA). All data were expressed as mean±SEM.
Diﬀerences were accepted as signiﬁcant when P<.05.
3. Results
3.1. Oxaprozin Increases Apoptosis of CD40L-Treated Mono-
cytes. NSAIDs have been previously shown to modulate
monocyte functions and monocytic cell survival [16, 17].
On the other hand, CD40 triggering has been already
shown to enhance monocyte survival [9]. Conﬁrming
these data, Figure 1(a) shows that 200ng/mL CD40L plus
1μg/mL CD40L enhancer induced a signiﬁcant (P<.05)
reductionofmonocyteapoptosisincomparisonwithcontrol
medium. Oxaprozin dose dependently increased CD40L-
treated monocyte apoptosis. 100μM oxaprozin induced the
strongest proapoptotic eﬀect. Oxaprozin-mediated activity
was also conﬁrmed using Annexin V and Propidium Iodide
assays, assessed by ﬂuorescence microscope and ﬂow cytom-
etry (Figure 1(b)). No signiﬁcant eﬀect on cell apopto-
sis/death was observed in untreated cells in the presence of
diﬀerent concentrations of oxaprozin (data not shown).
3.2. Oxaprozin Proapoptotic Eﬀect Is Independent of COX
Inhibition. To assess the possible role of COX in oxaprozin-
mediated proapoptotic activity, we studied other NSAIDs,
such as ibuprofen, indomethacin or naproxen. To inhibit
COX, we used these drugs at higher concentrations (100μM)
than their previously reported IC50 for COX-1 and -2 inJournal of Biomedicine and Biotechnology 3
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Figure 1: Oxaprozin increases apoptosis in CD40L-treated monocytes. Monocytes were incubated for 48 hours with control medium or
200ng/mL CD40L plus 1μg/mL CD40L enhancer in the presence or absence of diﬀerent doses (0, 5, 10, 50, 100μM) of oxaprozin. (a)
Assessment of apoptosis by acridine-orange-stained slides under ﬂuorescence microscopy. Data are express as percentages of apoptotic cells
on total number of cells counted (mean±SEM, n=3; apoptosis in absence versus in presence of CD40L: ∗P<.05; apoptosis in presence of
CD40L versus CD40L plus 10 or 50μM oxaprozin: #P<.05; apoptosis in presence of CD40L versus CD40L plus 100μM oxaprozin: ##P<.01).
(b) Assessment of apoptosis by using Annexin V and Propidium Iodide (PI) binding assay. (mean±SEM, n=4; apoptosis in absence versus
in presence of CD40L: ∗P<.05; apoptosis in presence of CD40L versus CD40L plus 100μM oxaprozin: #P<.05 and ##P<.01).
intactcells[18,19].100μMoxaprozinsigniﬁcantlyincreased
CD40L-treated monocyte apoptosis. Conversely, treatments
with ibuprofen, indomethacin, or naproxene did not induce
any eﬀect (Figure 2(a)) .T h e s ed a t aw e r ea l s oc o n ﬁ r m e d
using Annexin V and Propidium Iodide assay (Figure 2(b)).
No signiﬁcant eﬀect on cell apoptosis/death was observed in
untreatedcellsinthepresenceofdiﬀerentNSAIDsat100μM
(data not shown).
3.3. Oxaprozin Proapoptotic Activity Is Associated with the
Inhibition of CD40L-Triggered Akt and NF-κB Phosphoryla-
tion. In order to identify the intracellular pathway involved
in oxaprozin-mediated proapoptotic activity, we investi-
gated its possible modulatory eﬀect on CD40L-triggered
survival pathways. Figure 3(a) shows that CD40L-mediated
reduction of monocyte apoptosis was partially reversed by
pretreatment with LY294002 (PI3K inhibitor), PD98059
(MEK 1/2 inhibitor, a kinase activating ERK 1/2), SB203580
(p38 MAPK inhibitor), or SN-50 (NF-κB inhibitor). In
particular, the increase of monocyte apoptosis observed in
presence of only one of each selective inhibitor suggesting
that all signaling pathway activation is required for CD40L-
mediated antiapoptotic eﬀects. Annexin V and Propid-
ium Iodide assays conﬁrmed apoptosis levels morphologi-
cally assessed (Figure 3(b)). Oxaprozin treatment inhibited
CD40L-induced Akt and NF-κB (p65) phosphorylation
(Figure 3(c)). Conversely, a slight increase of ERK 1/2 and
p38 MAPK phosphorylation was observed in the presence
of oxaprozin in CD40L-simulated monocytes. No signiﬁcant
activation/inhibitiononproteinphosphorylationincompar-
ison with control medium was observed in the presence of
oxaprozin alone (data not shown). These data suggest that
oxaprozin treatment is associated with the inhibition of Akt
and NF-κB phosphorylation in CD40L-treated monocytes.
AlthoughcrucialinCD40L-inducedmonocytesurvival,ERK
1/2 and p38 MAPK are not involved in oxaprozin-mediated
proapoptotic eﬀects.
3.4. Oxaprozin Proapoptotic Activity Is Associated with Cas-
pase 3 Activation. We also investigated oxaprozin activity
on CD40L-mediated caspase 3 regulation, as a well-known
apoptotic pathway [20, 21]. According to apoptosis experi-
ments, oxaprozin treatment was associated with a signiﬁcant
increase of caspase 3 activity in CD40L-treated monocytes
(Figure 4(a)). To further conﬁrm the involvement of caspase
3 in oxaprozin-mediated proapoptotic activity, treatment
with caspase 3 inhibitor blocked oxaprozin-induced apopto-
sis in CD40L-treated monocytes (Figure 4(b)).4 Journal of Biomedicine and Biotechnology
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Figure 2: Oxaprozin-induced apoptosis is independent on COX inhibition. Monocytes were incubated for 48 hours with control medium or
200ng/mLCD40Lplus1μg/mLCD40Lenhancerinthepresenceorabsenceof100μMoxaprozin,100μMibuprofen,100μMindomethacin,
or 100μM naproxene. (a) Assessment of apoptosis by acridine-orange-stained slides under ﬂuorescence microscopy. Data are express,
as percentages of apoptotic cells on total number of cells counted (mean±SEM, n=4; apoptosis in absence versus in presence of
CD40L: ∗P<.05; apoptosis in presence of CD40L versus CD40L plus oxaprozin: #P<.05; apoptosis in presence of CD40L versus CD40L
plus other NSAIDs: N.S.). (b) Assessment of apoptosis by using Annexin V and Propidium Iodide (PI) binding assay (mean±SEM, n=3;
apoptosis in absence versus in presence of CD40L: ∗P<.05; apoptosis in presence of CD40L versus CD40L plus oxaprozin: #P<.05; apoptosis
in presence of CD40L versus CD40L plus other NSAIDs: N.S.).
4. Discussion
The induction of monocyte apoptosis rather than necrosis
might represent a crucial approach to chronic inﬂammatory
diseases, such as rheumatoid arthritis and atherosclero-
sis. In fact, in contrast to cells undergoing necrosis, the
contents of those undergoing apoptosis are not released
but cleared as apoptotic bodies by phagocytosis. On the
other hand, necrotic cell death promotes inﬂammation,
while apoptotic cell death results in an anti-inﬂammatory
condition. Therefore, immune cell apoptosis is actually
considered as a very promising anti-inﬂammatory thera-
peutic strategy [22]. On the other hand, CD40L represents
one of the most important mediators in inﬂammatory
processes modulating both infections and chronic diseases,
including atherosclerosis, rheumatoid arthritis and trans-
plantation [23–28]. CD40L has been already shown to
prolong monocyte survival [9]. CD40 is also present on
B cell, dendritic cell, monocyte, macrophage, mast cell,
ﬁbroblast, and endothelial cell membrane and regulates
several immune functions, such as B cell response, antigen
presenting cell activity, monocyte migration, and survival
[29–31]. These activities resulted from the binding with two
forms of CD40L. The ﬁrst form is expressed on activated
T and other immune cell membrane (CD154), while the
second one is a soluble form, also called soluble CD40 ligand
(sCD40L) [31]. Thus, given the pivotal role of monocytes
and sCD40L in inﬂammatory diseases, we investigated the
possible eﬀect of the NSAIDs on CD40L-induced monocyte
survival [32]. Among NSAIDs (drugs known for their potent
COX inhibitory activity), only oxaprozin dose dependently
increases apoptosis in CD40L-treated monocytes. This eﬀect
was observed at physiological concentrations achievable in
inﬂamed tissues [33]. These data suggest that a possible
molecularmechanismindependentofCOXinhibitionmight
be associated with oxaprozin proapoptotic eﬀect. To inhibit
COX, we used NSAIDs at higher concentrations (100μM)
than their previously reported IC50 for COX-1 and -2 in
intact cells [19]. In particular, IC50 of oxaprozin for human
platelet COX-1 and for human inteleukin-1 β stimulatedJournal of Biomedicine and Biotechnology 5
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Figure 3: Oxaprozin-induced apoptosis involves the inhibition of CD40L-induced Akt and NF-κB phosphorylation. Monocytes were incubated
for 48 hours with control medium or 200ng/mL CD40L plus 1μg/mL CD40L enhancer in the presence or absence of 50μM LY294002 (LY),
50μM PD98059 (PD), 1μM SB203580 (SB), or 20μM SN-50. (a) Assessment of apoptosis on cytopreps stained with acridine orange. Data
are expressed as percentages of apoptotic cells on total number of cells counted (mean±SEM, n=3, apoptosis in absence versus in presence
of CD40L: ∗∗P<.01; apoptosis in presence of CD40L versus CD40L plus PD: ##P<.01; apoptosis in presence of CD40L versus CD40L plus
LY or SB or SN-50:#P<.05). (b) Assessment of apoptosis using Annexin V and Propidium Iodide (PI) binding assay. Data are expressed
as percentages of positive cells on total number of cells counted (mean±SEM, n=2). (c) Monocytes were prencubated in the presence or
absence of 100μM oxaprozin for 1 hour and then stimulated with control medium or 200ng/mL CD40L plus 1μg/mL CD40L enhancer for
15 minutes. Then, cells were lysed, and western blot analysis was performed. Results represent one of three experiments that yielded similar
results.6 Journal of Biomedicine and Biotechnology
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Figure 4: Oxaprozin-induced apoptosis of CD40L-treated monocytes involves the activation of caspase 3. ( a )M o n o c y t e sw e r ec u l t u r e df o r4 8
hours with control medium or 200ng/mL CD40L plus 1μg/mL CD40L enhancer in the presence or absence of 100μM of oxaprozin. Then
cells were lysed, and caspase 3 activity was determined by spectrophotometer. Data are expressed as mean±SEM, n=3. (caspase 3 activity in
absence versus in presence of CD40L: ∗P<.05; caspase 3 activity in presence of CD40L versus CD40L plus oxaprozin: #P<.05). (b) Monocytes
were incubated for 48 hours with control medium or 200ng/mL CD40L plus 1μg/mL CD40L enhancer in the presence or absence 100μMo f
oxaprozin and 50μM Ac-DEVD-CHO (caspase 3 inhibitor, CASP 3 INHIB). Data are expressed as mean±SEM, n=3( a p o p t o s i si na b s e n c e
versus in presence of CD40L: ∗P<.05; apoptosis in presence of CD40L versus CD40L plus oxaprozin: #P<.05; apoptosis in presence of CD40L
plus oxaprozin versus CD40L plus oxaprozin and caspase 3 inhibitor: §P<.05).
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Figure 5:(a)CD40L-inducedmonocytesurvivalisassociatedwithAkt,ERK1/2,P38MAPKandNF-κBactivation,andcaspase3inhibition.
(b) Oxaprozin-induced apoptosis in CD40L-treated monocytes is associated with the inhibition of Akt and NF-κB and the activation of
caspase 3 pathways.Journal of Biomedicine and Biotechnology 7
synovial cell COX-2 were, respectively, 2.2±0.56μMa n d
36±28μM. These concentrations were similar to IC50
previously reported for the other NSAIDs in intact cells
[19]. Therefore, although oxaprozin biological activities are
commonly explained by the inhibition of COX, the lack
of proapoptotic activity of other NSAIDs suggests that
oxaprozin-induced increase of apoptosis in CD40L-treated
monocytes was not mediated by the inhibition of COX.
Then, we focused on COX-independent pathways [11].
Oxaprozin-mediatedbeneﬁcialeﬀectonmonocyteapoptosis
is associated with the inhibition of Akt and NF-κB and the
activation of caspase 3 pathways. This was suggested by two
diﬀerent ﬁndings: (1) CD40L-induced monocyte survival
was associated with the activation of PI3K-Akt, p38 MAPK,
NF-κB, and ERK 1/2 [34–38], and the activation of all
intracellular proteins was required to observe the increased
survival; (2) oxaprozin-increased apoptosis of CD40L-
stimulated monocytes was associated with the inhibition of
Akt and NF-κB. Apoptosis experiments with intracellular
protein inhibitors clearly indicate that each intracellular
molecule represents a potential target for the pharma-
cological inhibition of CD40L-induced proinﬂammatory
eﬀects. Although the inhibition of NF-κBw a sp r e v i o u s l y
reported, the association between oxaprozin treatment and
Akt inhibition in CD40L-stimulated monocytes represents a
novel ﬁnding. Surprisingly, we also showed that oxaprozin
treatmentwasassociated withanincreaseofCD40L-induced
ERK 1/2 and p38 MAPK phosphorylation. No signiﬁcant
increase/inhibition in comparison with control medium was
observed on ERK 1/2 or p38 MAPK phosphorylation in
the presence of oxaprozin alone. Thus, the pharmacological
increase of the activation of these kinases represents an
unexpected and novel ﬁnding, not completely understood.
Syntheticanti-inﬂammatorydrugshavebeenrecentlyshown
to increase MAPK activation in other cell types [39, 40].
However, much remains to be clariﬁed in this controversial
“activatory” approach [41]. Thus, it could represent an
interesting ﬁeld for future investigations. Finally, the present
article showed that oxaprozin treatment was associated
with an increase of caspase 3 activation in CD40L-treated
human monocytes. This has to be considered as a less
speciﬁc mechanism of apoptosis induction. In fact, caspase 3
represents the common ﬁnal pathway of apoptosis, in which
converges several pathways [42] and might correspond to
upstream oxaprozin-mediated events.
5. Conclusions
Oxaprozin has been shown as an eﬀective drug in the clinical
management of adult rheumatoid arthritis, osteoarthritis,
ankylosing spondylitis, soft tissue disorders, and postoper-
a t i v ed e n t a lp a i n[ 43]. In particular, oxaprozin treatment
showed better improvement in shoulder function and in the
mental health item of the SF-36 quality of life component
in comparison with diclofenac [44]. Beneﬁcial eﬀects of
oxaprozin might be due to the high rate of accumulation in
inﬂamed synovium in comparison with plasma and synovial
ﬂuid levels [33]. On the other hand, oxaprozin might be
also a more active drug than other NSAIDs. Both anti-
inﬂammatory and analgesic properties of oxaprozin are
mainly due to the potent inhibition of COX. However,
oxaprozin-induced beneﬁts might be also regulated by other
COX-independent pathways [11]. This approach could par-
tially explain the superior role of oxaprozin in comparison
with other NSAIDs. The present paper shows that oxaprozin
induceddirectproapoptoticeﬀectsinCD40L-treatedhuman
primary monocytes independently of COX inhibition. The
modulation of apoptotic mediators (such as Akt, NF-κB, and
caspase3)wasassociatedwithoxaprozin-mediatedproapop-
totic eﬀects (Figure 5). Although highly speculative, these
data support oxaprozin as a promising pharmacologic agent
tosuppressmonocytesurvivalandtheirdeleteriousactivities
in chronic inﬂammatory disorders, such as rheumatoid
arthritis.
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